02262nam a2200385Ia 4500001001200000003000600012005001700018007001400035008004100049040009100090043001200181074001900193088008900212086002200301110012000323245024700443260011400690300004500804336002600849337002700875338003100902500006000933500003600993504004101029500002501070500002501095533010401120650003801224650005701262650006101319610002601380610005001406776021801456776020201674ocm48715904OCoLC20180416115118.0he bmb024bbca020107s2001    dcua    bb   f000 0 eng d  aANGbengcANGdOCLCQdFXGBLdOCLCFdOCLCOdOCLCAdOCLCQdOCLCOdOCLCAdOCLCQdGPOdMvI  an-us---  a1019-B-01 (MF)  aSerial no. 107-30 (United States. Congress. House. Committee on Energy and Commerce)0 aY 4.C 73/8:107-301 aUnited States.bCongress.bHouse.bCommittee on Energy and Commerce.bSubcommittee on Oversight and Investigations.10aContinuing concerns over imported pharmaceuticals :bhearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Seventh Congress, first session, June 7, 2001.  aWashington :bU.S. G.P.O. :bFor sale by the Supt. of Docs., U.S. G.P.O. [Congressional Sales Office],c2001.  aiii, 191 pages :billustrations ;c24 cm  atextbtxt2rdacontent  amicroformbh2rdamedia  amicrofichebhe2rdacarrier  aDistributed to some depository libraries in microfiche.  aShipping list no.: 2002-0017-M.  aIncludes bibliographical references.  a"Serial no. 107-30."  aCRDP Program record.  aMicrofiche.b[Washington, D.C.] :cSupt. of Docs., U.S. G.P.O.,d[2001].e3 microfiches : negative. 0aDrugsxInspectionzUnited States. 0aDrug adulterationxGovernment policyzUnited States. 0aPharmaceutical industryzUnited StatesxQuality control.20aU.S. Customs Service.10aUnited States.bFood and Drug Administration.08iPrint version:aUnited States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations.tContinuing concerns over imported pharmaceuticalsw(DLC) 2001344162w(OCoLC)4784218608iOnline version:aUnited States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations.tContinuing concerns over imported pharmaceuticalsw(OCoLC)852784169